In recent decades, with the rapid development in tumor molecular biology, the mutations of the epidermal growth factor receptor (EGFR) and the abnormal fusion of the anaplastic lymphoma kinase (ALK) have been reported, which have been successfully applied in clinical settings as targeted therapies. The gene discussed is EGFR; the disease is neoplasm.